OncoMatch/Ovarian Cancer/BRCA1
Ovarian CancerBRCA1 Clinical Trials
Germline and somatic BRCA1 pathogenic variants are present in approximately 15–20% of high-grade serous ovarian carcinoma and define the most sensitive subgroup for PARP inhibitor therapy. PARP inhibitors including olaparib and niraparib are approved in biomarker-selected ovarian cancer maintenance settings; rucaparib has had narrower and changing ovarian indications. Trials investigate PARP inhibitor combinations with VEGF pathway agents (bevacizumab) and ATR/WEE1 inhibitors, and PARP inhibitor retreatment strategies after resistance.
Top recruiting BRCA1 Ovarian Cancer trials
Ranked by phase and US site count.
See all trials matched to your profile →Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NRG Oncology
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Roswell Park Cancer Institute
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Alexander B Olawaiye, MD
Autophagy Maintenance (AUTOMAIN)
Medical University of South Carolina
Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression
MedSIR
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
Qilu Hospital of Shandong University
More BRCA1 Ovarian Cancer trials
9 international trials (no US sites)
Browse other molecular targets with active Ovarian Cancer trials.